COPD trials in Japan

In Japan 13 Also abroad 559

13 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
Where
Chūōku, Fukuoka, Iizuka, Osaka, Sendai, Ube
Age
40 years to 75 years
People
606 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07759245 · EU 2026-525480-41-00
Phase 3Taking people
A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)
Where
Fukuoka, Tokyo
Age
40 years to 80 years
People
624 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07780669
Phase 2Taking people
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Where
Chiba, Fukuoka, Fukushima, Ginowan-shi, Hachioji-shi, Hamamatsu, Hiroshima, Izumi-shi, Kamakura, Kanazawa, Kasuga-shi, Kawasaki-shi, Kiyosu-shi, Kochi, Kōtoku, Kumamoto, Kusatsu-shi, Kyoto, Maebashi, Matsuyama, Minoh, Minokamo Shi, Miura, Mizunami-shi, Ōita, Osaka, Sagamihara-shi, Sapporo, Sasebo-shi, Shimotsuga-gun, Shinjuku-ku, Tachikawa-shi, Toon-Shi, Toyota, Ube, Yokkaichi-shi, Yokohama
Age
40 years and over
People
987 worldwide
Run by
AstraZeneca
See details and how to joinNCT07082738
Phase 2/3Taking people
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
Where
Fujieda, Fukuoka, Ginowan, Hachiōji, Hiroshima, Iizuka-shi, Kure, Nagoya, Sakai, Ube
Age
35 years to 80 years
People
1,156 worldwide
Run by
Pfizer
See details and how to joinNCT07363694 · EU 2024-518587-12-00
Phase 4Taking people
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
Where
Kyoto, Osaka, Ube
Age
40 years to 85 years
People
218 worldwide
Run by
Sanofi
See details and how to joinNCT07053423
Phase 3Taking people
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
Where
Chiba, Fujieda, Fukuoka, Fukushima, Hachiōji, Himeji-Shi, Hiroshima, Iizuka, Kagoshima, Kamakura, Kashihara, Kawasaki, Kita, Kiyose, Kobe, Kōnan, Kumamoto, Kure, Kurume, Kyoto, Matsusaka, Matsuyama, Nagoya, Okayama, Osaka, Saga, Sakai, Sakaidechō, Sapporo, Sendai, Takamatsu, Tokyo, Toyota, Ube, Ureshino-Shi, Yokohama, Yonezawa
Age
40 years to 80 years
People
942 worldwide
Run by
Sanofi
See details and how to joinNCT07190209 · EU 2024-518016-39-00
Phase 3Taking people
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
Where
Akashi-shi, Chikushino-shi, Chiyoda-ku, Fukui-shi, Fukuoka, Gifu, Iruma-Gun, Ishinomaki, Kasuga-shi, Kitakyushu-shi, Kiyose-shi, Kobe, Komatsu-shi, Kure-shi, Kyoto, Matsusaka-shi, Meguro-ku, Minatoku, Miyazaki, Mizunami-shi, Nagaoka-shi, Nagasaki, Nagoya, Nerima-ku, Ohta-ku, Okayama, Osaka, Sapporo, Sendai, Shinjuku-ku, Shiogama, Takamatsu, Takatsuiki-shi, Tanabe-shi, Toshima-ku, Ube, Yokohama
Age
40 years to 80 years
People
990 worldwide
Run by
AstraZeneca
See details and how to joinNCT06878261 · EU 2024-517457-27-00
Phase 3Taking people
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation
Where
Chiba, Fukuoka, Fukushima, Gifu, Hokkaido, Hyōgo, Ibaraki, Ishikawa, Kagawa, Kanagawa, Kitakyushu-shi, Kyoto, Mie, Nankoku-shi, Niigata, Okayama, Omuta Shi, Osaka, Shizuoka, Tokyo, Yamaguchi, Yokohama
Age
40 years to 80 years
People
981 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT06959095 · EU 2024-520418-22-00
Phase 3Taking people
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
Where
Chūōku, Fujieda-shi, Fukuoka, Kitakyushu, Kobe, Kure-shi, Kyoto, Minoh, Mizunami-shi, Okayama, Osaka, Osaki-shi, Sendai, Shinjuku-ku, Takamatsu, Yamagata, Yanagawa-shi, Yokohama
Age
40 years to 80 years
People
5,250 worldwide
Run by
AstraZeneca
See details and how to joinNCT06283966 · EU 2023-507407-59-00
No phaseTaking people
Zephyr Valve Japan Post-Marketing Surveillance
Where
Aichi, Gifu, Kanagawa, Kanazawa, Kawasaki, Mie, Nagasaki, Nagoya, Okayama, Osaka, Sapporo, Sendai, Shiga, Tokyo, Toyoake, Utsunomiya
Age
18 years and over
People
140
Run by
Pulmonx Corporation
See details and how to joinNCT06332885
Phase 3Taking people
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
Where
Gifu, Mie, Tokyo
Age
40 years to 75 years
People
1,196 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07177339 · EU 2025-521108-23-00
No phaseNot yet taking people in Japan
Improvement of Sleep in COPD Patients Through Inhalation Management Education by Nurse.
Where
Kumamoto
Age
20 years and over
People
60
Run by
Kumamoto University
See details and how to joinNCT07311499
No phaseTaking people
Sleep Hygiene, Sarcopenia, and Cognitive Function in Respiratory Disease
Where
Jōyō
Age
20 years and over
People
120
Run by
National Hospital Organization Minami Kyoto Hospital
See details and how to joinNCT05193136